IMPAHCT Aerovate AV-101-002. IMPAHCT: A Phase 2b/3, Randomized, Double-Blind, Placebo-Controlled, 24- Week Dose Ranging and Confirmatory Study to Evaluate the Safety and Efficacy of AV-101 in Patients with Pulmonary Arterial Hypertension (PAH).
Clinical Trial Grant
Administered By
Medicine, Pulmonary, Allergy, and Critical Care Medicine
Awarded By
Aerovate Therapeutics, Inc
Start Date
March 2, 2022
End Date
October 30, 2024
Administered By
Medicine, Pulmonary, Allergy, and Critical Care Medicine
Awarded By
Aerovate Therapeutics, Inc
Start Date
March 2, 2022
End Date
October 30, 2024